Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: Lessons learned for pharmacovigilance reporting

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Kabanywanyi, Abdunoor M ^a   Mulure, Nathan ^b   Migoha, Christopher ^c   Malila, Aggrey ^a   Lengeler, Christian ^e   Schlienger, Raymond ^d   Genton, Blaise ^a,e  

^a IFAKARA HEALTH INSTITUTE   (Tanzania)

^b Novartis Pharma Inc   (Kenya)

^c Tanzania Food and Drugs Authority   (Tanzania)

^d NOVARTIS PHARMA AG   (Switzerland)

^e SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMOXICILLIN; ARTEMETHER PLUS BENFLUMETOL; FANSIDAR; IVERMECTIN; METAKELFIN; PARACETAMOL; PENICILLIN G; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADOLESCENT; ADULT; AMNESIA; ARTICLE; CHILD; CLINICAL ARTICLE; CONVULSION; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSPNEA; DYSURIA; ERYTHEMA; EYELID EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; INFANT; INSOMNIA; JOINT STIFFNESS; MALARIA; MALE; MEDICAL EDUCATION; MUSCLE TWITCH; OBSERVATIONAL STUDY; PARAPLEGIA; PRESCHOOL CHILD; PRURITUS; REFRESHER COURSE; RESPIRATORY DISTRESS; RURAL AREA; SCHOOL CHILD; SIDE EFFECT; STIFF NECK; STILLBIRTH; TANZANIA; UNSPECIFIED SIDE EFFECT; VOMITING; DRUG COMBINATION; EDUCATION; HEALTH AUXILIARY; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROSPECTIVE STUDY; RURAL POPULATION; SAFETY; TELECOMMUNICATION;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; COMMUNITY HEALTH AIDES; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; LONGITUDINAL STUDIES; MALARIA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RURAL POPULATION; SAFETY MANAGEMENT; TANZANIA; TELECOMMUNICATIONS;

EID: 77955865085     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-205     Document Type: Article

References (35)

1. Safety monitoring of new anti-malarials in immediate post-marketing phase. IR Edwards, Med Trop (Mars) 1998 58 93 96 10212911
2. The importance of pharmacovigilance. WHO, 2010 http://apps.who.int/ medicinedocs/en/d/Js4893e/
3. Pharmacovigilance: methods, recent developments and future perspectives. L Harmark AC van Grootheest, Eur J Clin Pharmacol 2008 64 743 752 10.1007/s00228-008-0475-9 18523760
4. Pharmacovigilance from A to Z. Adverse drug event surveillance. B Cobert P Biron, Oxford: Blackwell Science 2002
5. Post-marketing surveillance: a UK/European perspective. S Gough, Curr Med Res Opin 2005 21 565 570 10.1185/030079905X41426 15899105
6. Intermittent preventive treatment of malaria during pregnancy: a qualitative study of knowledge, attitudes and practices of district health managers, antenatal care staff and pregnant women in Korogwe District, North-Eastern Tanzania. G Mubyazi P Bloch M Kamugisha A Kitua J Ijumba, Malar J 2005 4 31 10.1186/1475-2875-4-31 16033639
7. Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug. GM Mubyazi MA Gonzalez-Block, Malar J 2005 4 51 10.1186/1475-2875-4-51 16242017
8. Guidelines for the treatment of Malaria. WHO, 2006
9. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. C Falade M Makanga Z Premji CE Ortmann M Stockmeyer PI de Palacios, Trans R Soc Trop Med Hyg 2005 99 459 467 10.1016/j.trstmh.2004.09.013 15837358
10. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. I Zongo G Dorsey N Rouamba H Tinto C Dokomajilar RT Guiguemde PJ Rosenthal JB Ouedraogo, Lancet 2007 369 491 498 10.1016/S0140-6736(07)60236-0 17292769
11. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. KA Koram B Abuaku N Duah N Quashie, Acta Trop 2005 95 194 203 10.1016/j. actatropica.2005.06.018 16054584
12. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. A Martensson J Stromberg C Sisowath MI Msellem JP Gil SM Montgomery P Olliaro AS Ali A Bjorkman, Clin Infect Dis 2005 41 1079 1086 10.1086/444460 16163624
13. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. TK Mutabingwa D Anthony A Heller R Hallett J Ahmed C Drakeley BM Greenwood CJ Whitty, Lancet 2005 365 1474 1480 10.1016/S0140-6736(05)66417-3 15850631
14. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. G Dorsey S Staedke TD Clark D Njama-Meya B Nzarubara C Maiteki-Sebuguzi C Dokomajilar MR Kamya PJ Rosenthal, JAMA 2007 297 2210 2219 10.1001/jama.297.20.2210 17519410
15. Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. AM Kabanywanyi C Lengeler P Kasim S King'eng'ena R Schlienger N Mulure B Genton, Malar J 9 48 10.1186/1475-2875-9-48 20149235
16. Absence of seasonal variation in malaria parasitaemia in an area of intense seasonal transmission. T Smith JD Charlwood J Kihonda S Mwankusye P Billingsley J Meuwissen E Lyimo W Takken T Teuscher M Tanner, Acta Trop 1993 54 55 72 10.1016/0001-706X(93)90068-M 8103627
17. Effect of large-scale social marketing of insecticide-treated nets on child survival in rural Tanzania. JR Schellenberg S Abdulla R Nathan O Mukasa TJ Marchant N Kikumbih AK Mushi H Mponda H Minja H Mshinda, Lancet 2001 357 1241 1247 10.1016/S0140-6736(00)04404-4 11418148
18. Ifakara Demographic Surveillance System. 2009 http://www.indepth-network. org/dss-site-profiles/Ifakaraprofile.pdf
19. INDEPTH Efficacy and Safety Studies of Antimalarials in Africa. 2009 http://indepth-network.org/iness/
20. Diagnosis of malaria: challenges for clinicians in endemic and non-endemic regions. RN Bronzan ML McMorrow SP Kachur, Mol Diagn Ther 2008 12 299 306 18803428
21. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. M Makanga Z Premji C Falade J Karbwang EA Mueller K Andriano P Hunt PI De Palacios, Am J Trop Med Hyg 2006 74 991 998 16760509
22. A clinical and pharmacokinetic trial of six doses of artemether- lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. G Lefevre S Looareesuwan S Treeprasertsuk S Krudsood U Silachamroon I Gathmann R Mull R Bakshi, Am J Trop Med Hyg 2001 64 247 256 11463111
23. Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. AM Ibrahium MM Kheir ME Osman IF Khalil M Alifrangis KA Elmardi EM Malik I Adam, Ann Trop Med Parasitol 2007 101 15 21 10.1179/136485907X156924 17244406
24. Under-reporting of adverse drug reactions: a systematic review. L Hazell SA Shakir, Drug Saf 2006 29 385 396 10.2165/00002018-200629050-00003 16689555
25. Deploying artemether-lumefantrine with rapid testing in Ethiopian communities: impact on malaria morbidity, mortality and healthcare resources. H Lemma P Byass A Desta A Bosman G Costanzo L Toma E Fottrell AC Marrast Y Ambachew A Getachew, Trop Med Int Health 15 241 250 10.1111/j.1365-3156.2009. 02447.x 19961564
26. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. S Abdulla I Sagara S Borrmann U D'Alessandro R Gonzalez M Hamel B Ogutu A Martensson J Lyimo H Maiga, Lancet 2008 372 1819 1827 10.1016/S0140-6736(08)61492-0 18926569
27. Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials. EA Mueller M van Vugt W Kirch K Andriano P Hunt PI de Palacios, Acta Trop 2006 100 41 53 10.1016/j.actatropica.2006.09.007 17045558 (Pubitemid 44830005)
28. Spontaneous adverse drug reaction reporting in rural districts of Mozambique. E Sevene A Mariano U Mehta M Machai A Dodoo D Vilardell S Patel K Barnes X Carne, Drug Saf 2008 31 867 876 10.2165/00002018-200831100-00005 18759510
29. Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa. U Mehta D Durrheim A Mabuza L Blumberg E Allen KI Barnes, Drug Saf 2007 30 899 910 10.2165/00002018-200730100-00008 17867727
30. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. H Bukirwa S Nayiga R Lubanga N Mwebaza C Chandler H Hopkins AO Talisuna SG Staedke, Trop Med Int Health 2008 13 1143 1152 10.1111/j.1365-3156.2008.02119.x 18631312
31. Pharmacovigilance in developing countries. M Pirmohamed KN Atuah AN Dodoo P Winstanley, BMJ 2007 335 462 10.1136/bmj.39323.586123.BE 17823149
32. Understanding the pharmacokinetics of Coartem. A Djimde G Lefevre, Malar J 2009 8 Suppl 1 4 10.1186/1475-2875-8-S1-S4 19818171
33. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. F Ezzet R Mull J Karbwang, Br J Clin Pharmacol 1998 46 553 561 10.1046/j.1365-2125.1998.00830.x 9862244
34. Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects. G Lefevre P Carpenter C Souppart H Schmidli JM Martin A Lane C Ward D Amakye, J Clin Pharmacol 2002 42 1147 12362930
35. A practical handbook on the pharmacovigilance of antimalarial medicines. WHO, 2007